Welcome!
CNMC Goldmine Holdings
Broker's Calls

SAC Capital keeps ‘buy’ and leapfrogs target price on CNMC Goldmine Holdings to $1.13 from 45 cents previously
As at June 30, the company has US$37.3 million in net cash, which the analyst notes is a “record amount”. This accounts for 62% of its net asset value.
September 04, 2025
Results

CNMC reports record earnings of US$15.8 mil for 1HFY2025
CNMC CEO Chris Lim says the 1HFY2025 results "far exceeded" expectations
August 13, 2025
Broker's Calls

Brokers’ Digest: Sheng Siong Group, ST Engineering, Centurion, OCBC, CNMC Goldmine Holdings
See what the analysts have to say this week.
June 26, 2025
Broker's Calls

Lim & Tan Securities increases CNMC Goldmine’s target price to 48 cents after FY2024 results
On Feb 24, CNMC Goldmine announced earnings of US$9.8 million ($13.1 million) for the FY2024 ended Dec 31, 2024, 140.3% higher y-o-y. The bottom line was also the highest since CNMC's FY2015 results.
March 20, 2025
Broker's Calls

Brokers’ Digest: CLAR, CICT, CNMC Goldmine, KORE, Wilmar, Parkway Life REIT, FLCT, ST Engineering
See what the analysts have to say this week.
February 14, 2025
Results

CNMC Goldmine expects ‘significant improvement’ in profit guidance for FY2024
The company explains that the improvement is due to higher revenue from the sale of gold, as well as lead and zinc concentrate during the year.
January 21, 2025
Corporate moves

CNMC Goldmine ramps up production amid gold rally
The company will continue exploring its sites and is hopeful to uncover commercially viable opportunities.
May 23, 2024
Results

CNMC projects 'significant overall improvement' for its FY2023 earnings
Besides higher revenue from gold, CNMC generated revenue from lead and zinc concentrates
January 29, 2024
Contracts

CNMC Goldmine enters into 10-year sales contract with Yuchen Resources
Yuchen will purchase all lead, zinc and other concentrates or ore produced by CNMC at its Ulu Sokor concession from Jan 1, 2024.
December 22, 2023
IPO

Peter Choo-backed biomed firm CytoMed lists on Nasdaq
CytoMed Therapeutics was spun off from A*Star
April 17, 2023








